233 related articles for article (PubMed ID: 17141360)
1. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.
Hu JC; Sadeghi P; Pinter-Brown LC; Yashar S; Chiu MW
J Am Acad Dermatol; 2007 Feb; 56(2):317-26. PubMed ID: 17141360
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous side-effects of EGFR inhibitors and their management.
Ehmann LM; Ruzicka T; Wollenberg A
Skin Therapy Lett; 2011 Jan; 16(1):1-3. PubMed ID: 21293833
[TBL] [Abstract][Full Text] [Related]
3. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of cutaneous toxicities to EGFR inhibitors.
Lacouture ME
Nat Rev Cancer; 2006 Oct; 6(10):803-12. PubMed ID: 16990857
[TBL] [Abstract][Full Text] [Related]
5. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
Requena C; Llombart B; SanmartĂn O
Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
[TBL] [Abstract][Full Text] [Related]
6. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker.
Bianchini D; Jayanth A; Chua YJ; Cunningham D
Clin Colorectal Cancer; 2008 Jan; 7(1):33-43. PubMed ID: 18279575
[TBL] [Abstract][Full Text] [Related]
8. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
Galimont-Collen AF; Vos LE; Lavrijsen AP; Ouwerkerk J; Gelderblom H
Eur J Cancer; 2007 Mar; 43(5):845-51. PubMed ID: 17289377
[TBL] [Abstract][Full Text] [Related]
9. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors.
Balagula Y; Garbe C; Myskowski PL; Hauschild A; Rapoport BL; Boers-Doets CB; Lacouture ME
Int J Dermatol; 2011 Feb; 50(2):129-46. PubMed ID: 21244375
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous side-effects of kinase inhibitors and blocking antibodies.
Robert C; Soria JC; Spatz A; Le Cesne A; Malka D; Pautier P; Wechsler J; Lhomme C; Escudier B; Boige V; Armand JP; Le Chevalier T
Lancet Oncol; 2005 Jul; 6(7):491-500. PubMed ID: 15992698
[TBL] [Abstract][Full Text] [Related]
11. [Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors].
Tjin-A-ton ML; van Montfrans C; Koldenhof JJ; Sigurdsson V; Voest EE; Witteveen PO
Ned Tijdschr Geneeskd; 2007 Apr; 151(17):945-52. PubMed ID: 17520845
[TBL] [Abstract][Full Text] [Related]
12. Paronychia induced by the epidermal growth factor receptor inhibitor cetuximab.
Lee SL; Tan BS; Chan LC
J Oncol Pharm Pract; 2013 Sep; 19(3):273-8. PubMed ID: 23161875
[TBL] [Abstract][Full Text] [Related]
13. Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia.
Eames T; Grabein B; Kroth J; Wollenberg A
J Eur Acad Dermatol Venereol; 2010 Aug; 24(8):958-60. PubMed ID: 20015177
[TBL] [Abstract][Full Text] [Related]
14. Common side effects of anti-EGFR therapy: acneform rash.
Sipples R
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284
[TBL] [Abstract][Full Text] [Related]
15. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy.
Fox LP
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):26-34. PubMed ID: 16736980
[TBL] [Abstract][Full Text] [Related]
16. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
[TBL] [Abstract][Full Text] [Related]
17. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0.
Chen AP; Setser A; Anadkat MJ; Cotliar J; Olsen EA; Garden BC; Lacouture ME
J Am Acad Dermatol; 2012 Nov; 67(5):1025-39. PubMed ID: 22502948
[TBL] [Abstract][Full Text] [Related]
18. [Cutaneous side effects of EGF-receptor inhibition and their management].
Gutzmer R; Werfel T; Kapp A; Elsner J
Hautarzt; 2006 Jun; 57(6):509-13. PubMed ID: 16205868
[TBL] [Abstract][Full Text] [Related]
19. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
20. EGFR-targeted therapy and related skin toxicity.
Morse L; Calarese P
Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]